BOSTON, Aug. 29,
2023 /PRNewswire/ -- Haemonetics Corporation (NYSE:
HAE), a global medical technology company focused on delivering
innovative medical solutions to drive better patient outcomes, has
announced that for the first time, patients have been treated with
the company`s VASCADE MVP® Venous Vascular Closure
system in Germany. This marks the
first use of the VASCADE system portfolio, widely used in U.S.
hospitals, in a European country.
The VASCADE system is designed for "small-bore" femoral arterial
and venous closure, generally used in interventional cardiology and
peripheral vascular procedures. The VASCADE MVP system is designed
for "mid-bore" multi-access femoral venous closure, generally used
in electrophysiology procedures. Both closure devices are CE marked
under the EU-MDR (European Medical Device Regulations) for use in
patients who have undergone catheter-based procedures with single
or multiple access sites in one or both limbs and include
proprietary collapsible disc technology and a resorbable collagen
patch to achieve hemostasis. The VASCADE and VASCADE MVP systems
are designed to save time for hospital staff, while helping
patients reach hemostasis faster with fewer complications on
average compared to manual compression.
"First and foremost, the VASCADE MVP system helps promote
patient wellbeing. There is a very short post-procedural bedrest,
which can reduce back pain and the need for urinary catheters and
create the possibility for same-day discharge. From a handling
perspective, the VASCADE MVP device is logical to operate and has
smooth control. During the product evaluation, we achieved
hemostasis in the EP lab without the need of any further
compressive bandages," said Dr. Bogdan
Muntean, Senior Physician of Cardiology and Medical Director
of Electrophysiology at The Jewish Hospital in Berlin.
Haemonetics is planning further expansion for the VASCADE system
portfolio in other markets outside the U.S. Following the German
launch, the VASCADE systems have now been released for use in
Italy. Haemonetics recently
announced the distribution of the VASCADE MVP system in
Japan via an exclusive agreement
with Japan Lifeline Co. Ltd. The product is expected to launch in
Japan later this year.
"International commercialization of our VASCADE portfolio
represents an exciting milestone for our vascular closure business,
reinforcing our industry leadership in improving hospital
operations and raising standards of care for patients," said
Stewart Strong, President, Global
Hospital at Haemonetics. "We look forward to continuing to expand
our presence in global interventional cardiology and
electrophysiology markets to meet the ongoing needs of physicians
throughout the world."
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated
to providing a suite of innovative medical products and solutions
for customers, to help them improve patient care and reduce the
cost of healthcare. Our technology addresses important medical
markets: blood and plasma component collection, the surgical suite,
and hospital transfusion services. To learn more about Haemonetics,
visit www.haemonetics.com.
Cautionary Statement Regarding Forward-Looking
Information
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements in this press release may
include, without limitation, statements regarding plans and
objectives of management for the operation of Haemonetics,
including statements regarding potential benefits associated with
its VASCADE and VASCADE MVP systems and Haemonetics' plans or
objectives related to the development and commercialization of
these products. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
Haemonetics' current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences. Actual results and
the timing of certain events and circumstances may differ
materially from those described by the forward-looking statements
as a result of these risks and uncertainties. Factors that may
influence or contribute to the inaccuracy of the forward-looking
statements or cause actual results to differ materially from
expected or desired results may include, without limitation,
product quality and performance; market acceptance; the effect of
global economic and political conditions; the impact of
inflationary pressures in the company's global manufacturing and
supply chain; and the impact of competitive products and
pricing. These and other factors are identified and described in
more detail in Haemonetics' periodic reports and other filings with
the U.S. Securities and Exchange Commission. Haemonetics does not
undertake to update these forward-looking statements.
Investor
Contacts:
|
|
Olga Guyette, Sr.
Director-Investor Relations & Treasury
|
David Trenk,
Manager-Investor Relations
|
(781) 356-9763
|
(203)
733-4987
|
olga.guyette@haemonetics.com
|
david.trenk@haemonetics.com
|
|
|
Media Contact:
|
|
Josh Gitelson,
Director-Global Communications
|
|
(781) 356-9776
|
|
josh.gitelson@haemonetics.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-european-expansion-for-vascade-vascular-closure-system-301911791.html
SOURCE Haemonetics Corporation